A large number of studies have found that the overexpression of transmembrane proteins, namely, prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase, dominates in over 90% of prostate carcinomas and the tumor-associated endothelium of various solid cancer tissues9, 10. This evidence concerns the gene FOLH1 and neoplasm.